HUP0401561A2 - Anti-oszteopontin ellenanyag és használata - Google Patents

Anti-oszteopontin ellenanyag és használata

Info

Publication number
HUP0401561A2
HUP0401561A2 HU0401561A HUP0401561A HUP0401561A2 HU P0401561 A2 HUP0401561 A2 HU P0401561A2 HU 0401561 A HU0401561 A HU 0401561A HU P0401561 A HUP0401561 A HU P0401561A HU P0401561 A2 HUP0401561 A2 HU P0401561A2
Authority
HU
Hungary
Prior art keywords
antibody
osteopontin
drugs
integrin
recognizes
Prior art date
Application number
HU0401561A
Other languages
English (en)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Yukihiko Saeki
Yasuyuki Yokosaki
Masaki Noda
Nobuchika Yamamoto
Original Assignee
Immuno-Biological Laboratories Co., Ltd.
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno-Biological Laboratories Co., Ltd., Fujisawa Pharmaceutical Co., Ltd. filed Critical Immuno-Biological Laboratories Co., Ltd.
Publication of HUP0401561A2 publication Critical patent/HUP0401561A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anti-oszteopontin ellenanyag, ami képes gátolni a kötődést egyintegrin, ami felismeri az RGD-aminosavszekvencia helyet, és azoszteopontin, vagy annak fragmense között, valamint gátolni képes méga kötődést egy integrin, ami felismeri az SWYGLR-aminosavszekvencia,vagy annak megfelelő szekvenciahelyet, és az oszteopontin vagy annakfragmense között. Ez az ellenanyag jól használható autoimmun-betegségek elleni gyógyszerekben, reumaelleni gyógyszerekben és reumásarthritis elleni gyógyszerekben. Ez az ellenanyag jól használható adiagnosztizálásban és a reuma diagnosztikai módszerében. Ó
HU0401561A 2001-04-05 2002-04-04 Anti-oszteopontin ellenanyag és használata HUP0401561A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001107578 2001-04-05
JP2001290700 2001-09-25
PCT/JP2002/003382 WO2002081522A1 (fr) 2001-04-05 2002-04-04 Anticorps dirigé contre l'ostéopontine, et son utilisation

Publications (1)

Publication Number Publication Date
HUP0401561A2 true HUP0401561A2 (hu) 2004-11-29

Family

ID=26613159

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401561A HUP0401561A2 (hu) 2001-04-05 2002-04-04 Anti-oszteopontin ellenanyag és használata

Country Status (20)

Country Link
US (2) US20040234524A1 (hu)
EP (2) EP1375518B1 (hu)
JP (1) JP4230776B2 (hu)
KR (1) KR100881900B1 (hu)
CN (1) CN100469793C (hu)
AR (1) AR033121A1 (hu)
AT (1) ATE412013T1 (hu)
AU (1) AU2002244968B2 (hu)
BR (1) BR0208809A (hu)
CA (1) CA2443330A1 (hu)
CZ (1) CZ20032697A3 (hu)
DE (1) DE60229509D1 (hu)
ES (1) ES2314040T3 (hu)
HU (1) HUP0401561A2 (hu)
MX (1) MXPA03009052A (hu)
NO (1) NO20034405L (hu)
NZ (1) NZ528483A (hu)
PL (1) PL366469A1 (hu)
RU (1) RU2299888C2 (hu)
WO (1) WO2002081522A1 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090974A2 (de) * 2001-05-09 2002-11-14 Biovision Ag Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
AU2002330015B2 (en) 2001-09-18 2008-02-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003027151A1 (fr) * 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Anticorps recombinant anti-osteopontine et son utilisation
WO2006043954A1 (en) * 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
EP1637159A4 (en) * 2003-05-23 2009-01-21 Immuno Biological Lab Co Ltd IMMUNOMETIMENT CELL ACTIVATION INHIBITOR AND ITS USE
US20050042214A1 (en) * 2003-07-15 2005-02-24 Gershwin M. Eric Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
JP4871740B2 (ja) 2005-01-13 2012-02-08 株式会社ジーンテクノサイエンス 抗α９インテグリン抗体とその用途
MX2008015309A (es) * 2006-05-31 2009-03-02 Astellas Pharma Inc Anticuerpo humanizado de osteopontina anti-humana.
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
WO2007149948A2 (en) 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
CN101506239B (zh) 2006-07-12 2012-07-25 株式会社遗传科技 抗人α9整联蛋白抗体及其用途
WO2008032712A1 (en) 2006-09-11 2008-03-20 Immuno-Biological Laboratories Co., Ltd. Monoclonal antibody and use thereof
JP5399710B2 (ja) * 2006-10-26 2014-01-29 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに対する抗体およびその製法と用途
CN101293916A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
CN101293924A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
WO2009047283A2 (en) 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Means and methods for monitoring myocardial infarction and its treatment
KR101643005B1 (ko) 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
WO2009088105A1 (en) 2008-01-11 2009-07-16 Gene Techno Science Co., Ltd. HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF
US8603476B2 (en) 2008-01-11 2013-12-10 Astellas Pharma Inc. Humanized anti-human α9-integrin antibody
CN104530233B (zh) * 2008-04-24 2018-01-30 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
KR101599096B1 (ko) * 2009-02-23 2016-03-02 가부시키가이샤 진 테크노 사이언스 항인간 α９ 인테그린 항체와 그 용도
EP2406285B1 (en) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
WO2010131826A1 (ko) * 2009-05-12 2010-11-18 주식회사 이노파마스크린 오스테오폰틴 억제제 스크리닝 방법 및 그에 따른 억제제
EP2480665A4 (en) 2009-09-24 2013-04-03 Gene Techno Science Co Ltd HUMANIZED ANTIBODIES TO THE AMINO ACID SEQUENCE RGD OF EXTRACELLULAR MATRIX PROTEIN AND ITS USE
JP6215056B2 (ja) 2011-03-01 2017-10-18 ノヴォ ノルディスク アー／エス 拮抗性ｄｒ３リガンド
GB2493540A (en) 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
TWI738648B (zh) 2015-04-14 2021-09-11 日商中外製藥股份有限公司 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物
KR20220058554A (ko) * 2019-08-09 2022-05-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 오스테오폰틴에 대한 치료용 항체
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US63247A (en) * 1867-03-26 hbtdeick
US63241A (en) * 1867-03-26 Jacob green
US705842A (en) * 1901-10-25 1902-07-29 Daniel M Moroney Machine for assembling links in making chain belts.
US5459060A (en) * 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
EP0705842A2 (en) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
US6414219B1 (en) * 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
CA2370301A1 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Osteopontin-derived chemotactic and inhibitory agents and uses therefor
US7504232B2 (en) * 2000-03-23 2009-03-17 Smithkline Beecham Corporation Method of screening for inhibitors of osteopontin
WO2003027151A1 (fr) * 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Anticorps recombinant anti-osteopontine et son utilisation

Also Published As

Publication number Publication date
JP4230776B2 (ja) 2009-02-25
US20080069815A1 (en) 2008-03-20
RU2003132446A (ru) 2005-04-27
EP1375518A4 (en) 2004-12-08
NZ528483A (en) 2008-03-28
EP1754719A2 (en) 2007-02-21
EP1754719A3 (en) 2007-05-16
ATE412013T1 (de) 2008-11-15
BR0208809A (pt) 2004-03-09
CN1513000A (zh) 2004-07-14
RU2299888C2 (ru) 2007-05-27
CN100469793C (zh) 2009-03-18
NO20034405D0 (no) 2003-10-02
EP1375518B1 (en) 2008-10-22
AU2002244968B2 (en) 2007-07-26
WO2002081522A1 (fr) 2002-10-17
ES2314040T3 (es) 2009-03-16
NO20034405L (no) 2003-12-05
KR20030092022A (ko) 2003-12-03
MXPA03009052A (es) 2004-10-15
US20040234524A1 (en) 2004-11-25
KR100881900B1 (ko) 2009-02-04
PL366469A1 (en) 2005-02-07
DE60229509D1 (de) 2008-12-04
AR033121A1 (es) 2003-12-03
EP1375518A1 (en) 2004-01-02
JPWO2002081522A1 (ja) 2004-07-29
CZ20032697A3 (cs) 2004-01-14
CA2443330A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
HUP0401561A2 (hu) Anti-oszteopontin ellenanyag és használata
HUP0402049A2 (hu) Rekombináns anti-oszteopontin ellenanyag és annak használata
Ustun et al. Comments from WHO for the journal of rehabilitation medicine special supplement on ICF core sets
CY2014046I2 (el) Αντισωμα το οποιο δεσμευει αλφα4βητα7 ιντεγκρινη και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
CY1116256T1 (el) Il-17 ανταγωνιστικα αντισωματα
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
EA019476B9 (ru) АНТИТЕЛА ПРОТИВ IL-23p19 И ИХ ПРИМЕНЕНИЕ
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
SI2301965T1 (sl) Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
CY1109309T1 (el) Παραγωγα γλυκοπυρανοσυλοξυπυραζολης και χρηση αυτων σε φαρμακευτικα σκευασματα
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
SI1572087T1 (sl) Protitelesa proti antigenu tmeff2 raka in njihovauporaba
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
EA200700102A1 (ru) Лечение невропатической боли, фибромиалгии или ревматоидного артрита
EP2322559A3 (en) Neoplasm specific antibodies and uses thereof
DK1100829T3 (da) Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme
Miller Editorial Comment on: Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers by Otto et al.(From: Otto BJ, Bozorgmehri S, Kuo J, et al. J Endourol 2017; 31: 1335-1341)
Padma Side benefits sway developing nations to choose unneeded vaccines.
현한다 DDDD S
SE0201954D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy III
TH123607A (th) โมโนโคลนัลแอนติบอดี il-4 ในมนุษย์
SE0201960D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy X

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

Owner name: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

FD9A Lapse of provisional protection due to non-payment of fees